Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Share-based Compensation for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 26.01% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, up 22.59% year-over-year, with the annual reading at $11.7 million for FY2025, 22.59% up from the prior year.
  • Share-based Compensation for Q4 2025 was $2.0 million at TScan Therapeutics, down from $3.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $3.4 million in Q1 2025, with the low at $344000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $1.7 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 591.41% in 2021, then dropped 26.01% in 2025.
  • Over 5 years, Share-based Compensation stood at $784000.0 in 2021, then skyrocketed by 65.43% to $1.3 million in 2022, then increased by 15.65% to $1.5 million in 2023, then surged by 80.93% to $2.7 million in 2024, then decreased by 26.01% to $2.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.0 million, $3.0 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.